Summit Therapeutics Inc. (SMMT) has 29 open-market insider trades by 7 insiders since 2020. Over the last six months insiders net bought $103.6M. The most active filer is Robert W. Duggan, CEO & 10% Owner.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Robert W. Duggan | CEO10% Owner | — | 8 | $856.8M | 2026-06-12 |
| Mahkam Zanganeh | CEO10% Owner | — | 8 | $124.8M | 2026-06-12 |
| Yu Xia | Dir | — | 2 | $67.7M | 2025-10-21 |
| Maky Zanganeh | CEOPres | — | 2 | $15.3M | 2022-08-16 |
| Manmeet Singh Soni | COOCFO | — | 2 | $10.7M | 2026-06-04 |
| Ankur Dhingra | CFO | — | 5 | $879K | 2024-03-26 |
| David Jonathan Powell | CSO | — | 2 | $564K | 2020-11-30 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Robert W. Duggan | CEO & 10% Owner | Buy | $50.0M | 2026-06-12 |
| Mahkam Zanganeh | CEO & 10% Owner | Buy | $1.5M | 2026-06-04 |
| Manmeet Singh Soni | COO & CFO | Buy | $722K | 2026-06-04 |
| Mahkam Zanganeh | CEO | Buy | $1000K | 2025-10-21 |
| Yu Xia | Director | Buy | $20.0M | 2025-10-21 |
| Mahkam Zanganeh | CEO | Buy | $11.9M | 2025-09-10 |
Companies that share insiders with SMMT, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Mahkam Zanganeh | CEO | Buy | $539K | 2024-03-26 |
| Ankur Dhingra | CFO | Buy | $375K | 2024-03-26 |
| Ankur Dhingra | CFO | Buy | $44K | 2023-12-13 |
| Mahkam Zanganeh | CEO | Buy | $10K | 2023-12-12 |
| Manmeet Singh Soni | COO | Buy | $10.0M | 2023-10-13 |
| Mahkam Zanganeh | CEO & President | Buy | $42.3M | 2023-03-08 |
| Mahkam Zanganeh | CEO | Buy | $17.6M | 2023-03-08 |
| Ankur Dhingra | CFO | Buy | $412K | 2023-03-07 |
| Robert W. Duggan | CEO | Buy | $395.3M | 2023-03-06 |